×

Stocks Pfizer Inc

  • With all the chatter about moving away from equities into "safer" instruments like bonds or CDs, Cramer is giving viewers a reality check.

  • The Federal Reserve's pledge to keep interest rates at near zero for an extended period means US markets will continue to rise in early 2010, but asset bubbles and a shaky world economy will cause some investors to pull out of emerging markets, said Eric Ross of Watch Harbor Asset Management.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks advanced Monday, with the Nasdaq closing at a new 15-month high, after upgrades on Alcoa and Intel and as the Senate health-care bill advanced.

  • alzheimers1_200.jpg

    This morning biopharma P & A reached critical mass. In a rare, holiday-week confluence, four major pharmaceutical companies announced partnership deals and one announced a nearly $2-billion acquisition. All of the partnerships are on drugs that are still in the testing stage. If they were to all come to fruition, which in the risky business of drug development is highly unlikely, the new partnerships could collectively be worth billions of dollars over time.

  • Healthcare coverage and the hastle of forms

    There is nothing in this bill that changes our views at Soleil regarding the health care stocks we have been recommending.

  • Cramer makes the call on viewers' favorite stocks.

  • Winterizing Your Portfolio - A CNBC Special Report

    Techs rallied Friday after strong earnings reports from Oracle and Research In Motion. But the Dow erased its gains.

  • 2009's Dogs of the Dow—the top 10 Dow stocks whose dividend is the highest fraction of their price—failed to beat the market this year. So will the same be true in 2010? Paul Hickey, co-founder of Bespoke Investment Group, shared his view.

  • I'm on Amtrak's Acela (the faster train) to Boston to do an exclusive interview tomorrow with Genzyme Chairman and CEO Henri Termeer. It'll be live on "Power Lunch" around 1:30p ET. I was planning on spending the train trip reading up on GENZ, but I got easily sidetracked by the Auxilium news.

  • Eli Lilly did the expected today, but investors were hoping for more. Bears mauled the drug maker, unloading shares and snapping up puts, after management failed to address concerns about major patent expirations beginning in 2011.

  • Senate Democrats came to an agreement on Tuesday to replace the controversial government-run public insurance option with a scaled-back non-profit plan. So which companies in the health care sector are worth investing in? John Sullivan, director of research and health care investment strategist at Leerink Swann, shared his insight.

  • Cramer makes the call on viewers' favorite stocks.

  • Cash is King!  Whether you are a bull or a bear, having cash on hand helps companies weather downturns or invest in the future.  Here are the S&P 500 companies with the biggest cash positions.

  • Following months of negotiations, General Electric and Comcast announced today a definite agreement to form a joint venture.  Here is a look at the top 10 M&A transactions this year.

  • microscope_200.jpg

    Normally things tend to slow down a bit between Thanksgiving and New Year's Day. But this week alone we've already seen two biopharma partnership deals in as many days. First Pfizer and Protalix and now AstraZeneca and Targacept.

  • In today's trading session, a total of 55 stocks in the S&P 500 reached new 52-week highs. Here is a look at those companies.

  • Following are the day’s biggest winners and losers. Find out why shares of Pfizer and Guess? popped while Human Genome and DynCorp dropped.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks kicked off December with a rally Tuesday as Dubai fears subsided and the dollar retreated, pushing gold to a new record above $1,200 an ounce. The Dow gained 1.2 percent to close at its highest level since Oct. 2008.

  • Pfizer

    Pfizer today announced it's paying what amounts to chump change (a total of $115 million over time) for the rights to a biotech drug to treat a rare disease. And as I write this, investors are rewarding the world's biggest drug company by making its stock the biggest percentage gainer among the Dow 30.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks kicked off December with a rally Tuesday as Dubai fears subsided and the dollar retreated, pushing gold to a new record above $1,200 an ounce.